Figure 2D shows that some of the most enriched pathways in the case of GLI1 and GLI2 overexpression are Wnt signaling pathway, MAPK signaling pathway, and Ras signaling pathway. About 20–30% of DEGs are involved in these signaling pathways. An even bigger percentage of genes (30–40%) show involvement in Neuroactive ligand−receptor interactions. There is also significant involvement of DEGs in different cancer types (Figure 2D, Supplementary Figure S4). The gene discussed is GLI2; the disease is cancer.